Tissue-specific methylation marker
AssigneeGrail, LLC
InventorsYuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Kwan Chee Chan, Wanxia Gai, Lu Ji
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions comprising tissue-specific markers for identifying a tissue of origin of a cell-free nucleic acid, e.g., a cell-free DNA molecule. Also provided herein are methods, compositions, and systems for identifying a tissue of origin of a cell-free nucleic acid by determining an absolute amount of cell-free nucleic acids comprising the tissue-specific marker. Also provided herein are methods, compositions, and systems for detecting a cancer in a tissue of an organism by analyzing tissue-specific markers.
Claims20
A method of detecting and treating a metastasis in a subject, the method comprising selecting a subject having a metastasis of a cancer with a tissue of origin, and administering a treatment to the subject effective to treat the metastasis, wherein:
- (a) the selecting comprises (i) receiving results of an assay of a first biological sample of the subject measuring an absolute amount of cell-free DNA comprising a target sequence having a first methylation status (ii) identifying the measured absolute amount as being above a reference amount, and (iii) identifying a first non-cancer tissue as a location of the metastasis;
- (b) the first biological sample comprises cell-free DNA molecules from the cancer, the first non-cancer tissue, and one or more second non-cancer tissues;
- (c) the tissue of origin, the first non-cancer tissue, and the one or more second non-cancer tissues are different;
- (d) cell-free DNA molecules from the first non-cancer tissue comprise the first methylation status of the target sequence;
- (e) the first methylation status is distinct from one or more second methylation statuses of the target sequence in cell-free DNA molecules from the cancer and from the one or more second non-cancer tissues;
- (f) the reference amount is an absolute amount of cell-free DNA comprising the target sequence having the first methylation status for one or more subjects without metastasis in the first non-cancer tissue;
- and
- (g) the treatment is selected from the group consisting of chemotherapy, radiation therapy, surgical removal of tumor tissues, immunotherapy, hormone therapy, and stem cell therapy.
Dependencies are inferred from the claim text.